Top Tech Companies (764)
Don't see your company?
Create a company profile
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts
Enriching Lives Through Personalized Medicine and Care Doing the right thing... in the right way... at the right time... in the right place... for the right person... with the right feeling... the first time. Akina Specialty Compounding Pharmacy is purpose driven to provide healthcare providers and their patients with the most meticulously sterile and non-sterile compounded medications and exceptional service.
Nobelpharma develops medicines and medical devices with a focus on underserved patient populations and undertreated medical conditions. Visit our website at https://www.nobelpharma-us.com
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.
Our Acadia family of care-ageous warriors aspire to enable brighter moments for patients and their loved ones. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Important Notice for Candidates - Be Aware of Fraudulent Recruiting Activity Acadia Pharmaceuticals has become aware of fraudulent recruiting activity being circulated via email and LinkedIn by individuals impersonating Acadia Talent Acquisition employees. These communications may appear legitimate due to an official-looking Acadia email address or website, referencing of an actual recruiter and/or manager at Acadia (easily found on LinkedIn), and/or offer documents falsely signed by an Acadia executive. The impostor uses the incentive of a job interview and job offer to solicit sensitive personal information from the intended victim. Please note that the Acadia Talent Acquisition and HR Team will ONLY interact with a candidate from "Acadia-pharm.com" domain sourced emails. We do not request sensitive personal information, such as a Social Security Number, or payments of any kind during the interview or job offer process. Acadia strongly recommends individuals, who receive email solicitations, to carefully verify the authenticity of the correspondence before responding. Never provide personal information or click on links if you are unsure a communication’s legitimacy. If in doubt, please contact [email protected] to verify.
Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). Our world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing novel cancer therapies to market. A science-first mindset and patient-centric approach is in our genes. With a growing pipeline of studies, we remain dedicated to developing products for cancers with mTOR pathway driver alterations. For more information, please visit: https://aadibio.com/
Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.
In 1921, Guy Hollister, a chemist, and Dr. Robert Stier, a pathologist, developed a treatment to bring relief to the allergy suffering in their own families. From those beginnings a company dedicated to putting an end to allergy suffering was born, HollisterStier Allergy. Over the years that focus has not wavered, and our quest for better ways to do things continues. We take pride in the quality of our extracts, and our research and development group continually looks at ways to improve them. Our constant search for better ways to do things and an overwhelming need to help allergy sufferers get more out of life have led us to some unique products like our multiple skin test devices, and our phenol free antigens. And we are working on all kinds of other great new ideas.
Isolation Sciences is a developer of energy and safety risk management isolation and containment products.
.jpeg)
.png)
Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
AIT Bioscience offers bioanalytical contract research services for preclinical and clinical trials.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Magellan Health is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators.
PharmaLink is a pharmaceutical reverse logistics and disposal provider.
Aktiv Pharma Group brings peace of mind to people at risk and their communities by developing simple-to-use emergency treatment technologies. Initially developed for the military, the ARAI™ is a prefilled auto-injector that uses single-hand, single-step activation. Now, ARAI is being developed to help people with life-threatening conditions in emergency situations, such as hypoglycemia, anaphylaxis and opioid overdose. Aktiv's platform technology has been used in a variety of form factors—including pre-filled syringes, auto-injectors, oral and topical dispensers, and IV transfer systems—which serve a broad range of medical applications. The flexible platform can be configured to carry a single drug solution or individually store multiple drug constituents that are either injected separately or automatically mixed just prior to injection. To learn more about career or investment opportunities, please visit www.aktivax.com.
Network Solutions - Original domain name registration and reservation services with variety of internet-related business offerings. Quick, dependable and reliable.
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities
CinRx Pharma is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success by accelerating promising new medicines to patients. Integrating our pre-clinical, clinical and operational expertise with multiple shots on goal, we customize the optimal development trajectory for each pipeline candidate – a drug development superhighway. Our deliberate approach to asset selection is driven by deep operational and scientific expertise combined with decades of experience treating patients and developing new drugs. We invest in candidate drugs that have the potential for transformational change in the way a disease area is treated and significantly improves the patient experience and quality of life.
MediciNova is a biopharmaceutical company that acquires and develops novel, small-molecule therapeutics.
